dc.contributor.author | Gaibar Alonso, María | |
dc.contributor.author | Novillo, Apolonia | |
dc.contributor.author | Romero Lorca, Alicia | |
dc.contributor.author | Malón, Diego | |
dc.contributor.author | Antón, Beatriz | |
dc.contributor.author | Moreno, Amalia | |
dc.contributor.author | Fernández Santader, Ana | |
dc.date.accessioned | 2022-02-23T09:21:58Z | |
dc.date.available | 2022-02-23T09:21:58Z | |
dc.date.issued | 2021 | |
dc.identifier.issn | 1999-4923 | spa |
dc.identifier.uri | http://hdl.handle.net/10641/2854 | |
dc.language.iso | eng | spa |
dc.publisher | Pharmaceutics | spa |
dc.rights | Atribución-NoComercial-SinDerivadas 3.0 España | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/3.0/es/ | * |
dc.subject | HER2-positive breast cancer | spa |
dc.subject | Anti-HER2 treatment | spa |
dc.subject | FGFR1 gene | spa |
dc.subject | Pathological complete response | spa |
dc.subject | Miller–Payne grading | spa |
dc.title | FGFR1 Amplification and Response to Neoadjuvant Anti-HER2 Treatment in Early HER2-Positive Breast Cancer. | spa |
dc.type | journal article | spa |
dc.type.hasVersion | AM | spa |
dc.rights.accessRights | open access | spa |
dc.description.extent | 262 KB | spa |
dc.identifier.doi | 10.3390/pharmaceutics14020242 | spa |
dc.relation.publisherversion | https://www.mdpi.com/1999-4923/14/2/242 | spa |